These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 6 of 7 substances referred to collectively as the Siloxanes Group.
|Substance group||CAS RN||Common name||DSL name||Draft screening assessment||Proposed conclusion on section 64 criteria||Follow-up activities|
|Siloxanes Group||107-46-0||Hexamethyldisiloxane (L2)||Disiloxane, hexamethyl-||HTML||Does not meet||None planned at this time|
|141-62-8||Decamethyltetrasiloxane (L4)||Tetrasiloxane, decamethyl-|
|141-63-9||Dodecamethylpentasiloxane (L5)||Pentasiloxane, dodecamethyl-|
|541-05-9||Cyclotrisiloxane (D3)||Cyclotrisiloxane, hexamethyl-|
|2627-95-4||Divinyltetramethyldisiloxane (dvTMDS)||Disiloxane, 1,3-diethenyl-1,1,3,3-tetramethyl-|
|69430-24-6Table 1 Footnote a||Cyclomethicone||Cyclosiloxanes, di-Me|
|June 2020||Anticipated publication of the final screening assessment.|
|June 1, 2019||Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 22.|
A seventh substance, CAS RN 33204-76-1, was initially identified as being part of the Siloxanes Group at the outset of the third phase of the CMP. This substance was subsequently determined to be of low concern to both human health and the environment through other approaches. Conclusions for this substance are provided in the Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure.
Report a problem or mistake on this page
- Date modified: